Retatrutide is a first-in-class triple hormone receptor agonist developed by Eli Lilly that targets GIP, GLP-1, and glucagon receptors simultaneously. In clinical trials, it has produced the most dramatic weight loss results of any obesity medication tested to date — up to 24.2% body weight reduction at 48 weeks in Phase 2 and up to 28.7% at 68 weeks in Phase 3. But these results were not achieved by jumping straight to the highest retatrutide dosage. They were achieved through a carefully structured dose escalation protocol that took weeks to complete.
Understanding the retatrutide dosage schedule matters because the difference between a tolerable experience and a miserable one often comes down to how quickly the dose is increased. In this article, we break down the complete dose escalation protocol from clinical trials, explain what happens at each dose level, and outline the blood tests that should accompany every stage of treatment.
Key Takeaways
- Retatrutide dosage escalation follows a structured 4-week step-up protocol, starting at 2 mg and increasing every 4 weeks until the target maintenance dose is reached.
- The full escalation to 12 mg takes approximately 16–20 weeks, passing through 2 mg, 4 mg, 6 mg, and 9 mg steps before reaching the maximum dose.
- Weight loss is progressive: Phase 2 data showed −7.2% at 1 mg, −12.9% at 4 mg, −17.3% at 8 mg, and −17.5% at 12 mg by week 24 — with losses continuing to −24.2% at 12 mg by week 48.
- Side effects peak during escalation and are dose-dependent. Starting at 2 mg instead of 4 mg significantly reduced gastrointestinal symptoms in clinical trials.
- Blood tests are essential before starting and at each dose transition to monitor liver, kidney, thyroid, and pancreatic function.
- Phase 3 TRIUMPH trials use a refined escalation schedule (2 mg → 4 mg → 6 mg → 9 mg → 12 mg) with results showing up to 28.7% weight loss at 68 weeks.
How Retatrutide Dosing Works
Retatrutide is administered as a once-weekly subcutaneous injection. Unlike some medications where you start at the treatment dose, retatrutide uses a gradual dose escalation (also called titration) protocol. This means patients begin at a low dose and increase it in defined steps over several weeks until they reach their target maintenance dose.
The rationale is straightforward. Retatrutide activates three different hormone receptors — GIP, GLP-1, and glucagon — each of which affects gut motility, appetite, blood sugar regulation, and energy expenditure. Introducing the drug gradually gives the body time to adapt to each receptor’s activation, reducing the severity of gastrointestinal side effects that are the most common reason patients discontinue incretin-based therapies.
In the Phase 2 obesity trial (Jastreboff et al., NEJM 2023), the investigators compared two starting approaches for higher-dose groups: some participants began at 2 mg and others at 4 mg. The finding was clear — starting at 2 mg produced significantly fewer gastrointestinal side effects while achieving equivalent weight loss at 48 weeks. This informed the Phase 3 TRIUMPH trial design, where all participants start at 2 mg regardless of their target dose.
Phase 2 vs. Phase 3 Escalation Schedules
The Phase 2 and Phase 3 trials used slightly different dose steps. The Phase 2 trial tested doses of 1 mg, 4 mg, 8 mg, and 12 mg, with escalation in 4-week intervals. The Phase 3 TRIUMPH programme refined this to target doses of 4 mg, 9 mg, and 12 mg, using intermediate steps of 2 mg, 4 mg, and 6 mg. The 9 mg dose replaced the 8 mg dose tested in Phase 2, and the addition of a 6 mg step created a smoother escalation curve.
The Retatrutide Dose Escalation Chart
The following chart shows the dose escalation schedule used in the Phase 3 TRIUMPH clinical trial programme for participants targeting the maximum 12 mg retatrutide dosage. Each dose level is maintained for 4 weeks before the next increase.
| Week | Dose | Phase | Common Side Effects | Cumulative Weight Loss* |
|---|---|---|---|---|
| 1–4 | 2 mg | Initiation | Mild nausea (14%), decreased appetite | −2 to −3% |
| 5–8 | 4 mg | Escalation | Nausea (18–36%), mild diarrhoea, constipation | −5 to −7% |
| 9–12 | 6 mg | Escalation | Nausea (30–40%), vomiting, injection site reactions | −8 to −11% |
| 13–16 | 9 mg | Escalation | Nausea (40–50%), diarrhoea, dysesthesia (8.8%) | −12 to −15% |
| 17–20 | 12 mg | Target dose reached | Nausea (45–60%), vomiting (26%), dysesthesia (20.9%) | −15 to −18% |
| 21–48 | 12 mg | Maintenance | GI symptoms stabilise and diminish over time | −24.2% (wk 48) |
| 49–68 | 12 mg | Maintenance (Phase 3) | Side effects generally well tolerated at steady state | −28.7% (wk 68) |
*Cumulative weight loss percentages are approximate estimates derived from Phase 2 (Jastreboff et al., NEJM 2023) and Phase 3 TRIUMPH-4 trial data. Individual results varied. Side effect rates from Phase 2 trial data for 12 mg target dose group (2 mg starting dose).
Why Dose Escalation Matters
Dose escalation is not a formality — it is the difference between a treatment that patients can sustain and one they abandon. The Phase 2 trial provided direct evidence by randomising participants to different starting doses within the same target-dose groups.
The 2 mg vs. 4 mg Starting Dose Finding
In the 8 mg target group, participants who started at 2 mg and escalated gradually experienced markedly fewer GI side effects than those who started at 4 mg. The nausea rate difference was striking: 17% in the 2 mg-start group versus 60% in the 4 mg-start group during the escalation phase. Yet at 48 weeks, both groups achieved equivalent weight loss (−22.1% vs. −22.8%).
This means the slower start sacrificed nothing in efficacy while dramatically improving tolerability. It is the strongest piece of evidence supporting gradual dose escalation.
Beyond tolerability, dose escalation serves three additional purposes. First, it allows the gastrointestinal tract to adapt to GLP-1 receptor activation, which slows gastric emptying. Second, it gives clinicians time to identify patients who may be unusually sensitive to the drug before they reach high doses. Third, it provides natural checkpoints for blood testing to monitor organ function at each new exposure level.
The discontinuation data reinforce this. In the Phase 2 trial, discontinuation due to adverse events was 6% at 1 mg and 16% at 12 mg — and most discontinuations occurred during the escalation phase, not during maintenance. Once patients reached their target dose and their bodies had adapted, most could continue treatment without issue.
What Happens at Each Dose Level
2 mg — The Starting Dose (Weeks 1–4)
The 2 mg dose is the initiation phase. At this level, the drug begins activating GIP, GLP-1, and glucagon receptors at a low intensity. Most participants notice a reduction in appetite within the first 1–2 weeks. Side effects are generally mild: nausea in approximately 14% of participants (comparable to the 11% seen in placebo groups), with occasional mild diarrhoea or constipation.
Weight loss at this stage is modest but detectable — typically 2–3% of body weight over 4 weeks. The primary purpose of this phase is adaptation, not dramatic results. The body is calibrating its response to triple receptor activation.
4 mg — First Escalation (Weeks 5–8)
The first dose increase is where most patients begin to notice the drug’s appetite-suppressing effects more clearly. Nausea rates increase to 18–36% (depending on whether participants started at 2 mg or 4 mg initially). Decreased appetite becomes more pronounced, and some participants report early satiety — feeling full after smaller meals.
In the Phase 2 trial, the 4 mg dose groups achieved a mean weight loss of −12.9% at 24 weeks and −17.1% at 48 weeks. For participants whose target dose was 4 mg, this is the maintenance phase. For those escalating further, the 4 mg dose continues the adaptation process. Diarrhoea (20%), constipation (15%), and vomiting (12%) are the other notable side effects at this level.
6 mg — Intermediate Step (Weeks 9–12)
The 6 mg dose was introduced in the Phase 3 TRIUMPH programme as an additional intermediate step between 4 mg and 9 mg. It was not tested as a standalone target dose in Phase 2 but serves as a critical bridge that prevents patients from making a large jump from 4 mg to 8 mg (or 9 mg) in a single step.
At this level, the glucagon receptor activation becomes more noticeable. This is the receptor responsible for increased energy expenditure and hepatic fat mobilisation — effects that distinguish retatrutide from pure GLP-1 agonists like semaglutide. Gastrointestinal symptoms are moderate, and injection site reactions may become more apparent (approximately 5–7% of participants).
9 mg — High Dose (Weeks 13–16)
The 9 mg dose (replacing the 8 mg tested in Phase 2) represents the beginning of high-dose territory. In TRIUMPH-4, participants at 9 mg achieved −26.4% mean weight loss at 68 weeks — equivalent to an average of 29.1 kg (64.2 lbs) lost. Gastrointestinal side effects are more common at this level, with nausea rates of approximately 40–50%.
A notable side effect that emerges more clearly at 9 mg is dysesthesia — tingling, altered skin sensation, or a pins-and-needles feeling. In TRIUMPH-4, this affected 8.8% of participants at the 9 mg dose. This effect is thought to be related to glucagon receptor activation and is largely unique to retatrutide among incretin-based therapies. For a more detailed discussion, see our article on retatrutide side effects.
12 mg — Maximum Dose (Weeks 17–20 and Beyond)
The 12 mg dose is the highest tested in clinical trials and the dose at which the most impressive weight loss results have been observed. In Phase 2, participants at 12 mg lost −17.5% at 24 weeks and −24.2% at 48 weeks. In Phase 3 TRIUMPH-4, the 12 mg group achieved −28.7% weight loss at 68 weeks — an average of 32.3 kg (71.2 lbs).
Side effects are most prevalent at this dose. In Phase 2, nausea affected up to 60%, vomiting 26%, diarrhoea 15%, and constipation 16%. Dysesthesia was reported in 20.9% of participants at 12 mg in TRIUMPH-4. However, the critical detail is that most of these side effects occurred during the escalation phase and diminished after participants stabilised at their maintenance dose.
Heart rate increases were also dose-dependent, with a mean increase of 5–10 beats per minute at 12 mg, peaking around week 24 and declining thereafter. Despite these effects, the serious adverse event rate was 4% — identical to the placebo group.
Side Effects by Dose: A Comparison
The following table summarises how side effect rates change across retatrutide dosage levels, based on Phase 2 trial data (Jastreboff et al., NEJM 2023). Dysesthesia rates are from the Phase 3 TRIUMPH-4 trial.
| Side Effect | Placebo | 1 mg | 4 mg | 8 mg | 12 mg |
|---|---|---|---|---|---|
| Nausea | 11% | 14% | 36% | 44% | 60% |
| Diarrhoea | 11% | 9% | 20% | 20% | 15% |
| Vomiting | 1% | 3% | 12% | 12% | 26% |
| Constipation | 3% | 7% | 15% | 11% | 16% |
| Decreased appetite | 3% | 5% | 9% | 11% | 14% |
| Injection site reactions | 0% | 1% | 5% | 7% | 8% |
| Dysesthesia* | 0.7% | — | — | 8.8% | 20.9% |
| Discontinuation rate | 0% | 6% | 10% | 11% | 16% |
*Dysesthesia rates from Phase 3 TRIUMPH-4 trial (9 mg and 12 mg dose groups). Dashes indicate dose not tested in that trial.
The most important pattern here is that while side effects increase with dose, they are predominantly mild to moderate and occur mainly during the escalation phase. The serious adverse event rate was 4% across all retatrutide groups — the same as placebo. For a comprehensive analysis, see our full guide to retatrutide side effects.
Blood Tests at Each Stage of Dose Escalation
Regular blood testing is an essential component of safe dose escalation. In clinical trials, laboratory assessments were performed at baseline and at regular intervals throughout treatment. The following biomarkers are particularly relevant when monitoring retatrutide dosage changes:
| Biomarker Category | Key Tests | Why It Matters for Retatrutide |
|---|---|---|
| Liver function | ALT, AST, GGT, bilirubin | Transient ALT elevations (>3x upper limit) reported in 1% of participants. Glucagon activation drives hepatic fat mobilisation. |
| Kidney function | Creatinine, eGFR, urea | GI side effects (vomiting, diarrhoea) can cause dehydration, which may temporarily affect kidney markers. |
| Pancreatic enzymes | Amylase, lipase | Pancreatitis is a class-effect concern for all incretin therapies. One case reported at 12 mg in Phase 2. |
| Thyroid hormones | TSH, free T4, free T3 | Incretin therapies carry a precautionary thyroid warning (based on rodent data). Monitoring recommended at baseline and periodically. |
| Blood sugar | HbA1c, fasting glucose | Retatrutide significantly reduces HbA1c. Important for patients at risk of or managing type 2 diabetes. |
| Lipid panel | Total cholesterol, LDL, HDL, triglycerides | Clinical trials showed significant improvements in lipid profiles, particularly triglyceride reduction. |
| Full blood count | Haemoglobin, WBC, platelets | General health baseline. Rapid weight loss can affect haematological parameters. |
Recommended Testing Schedule
Baseline (before starting): Full panel including all categories above. This establishes your reference values.
At each dose increase (every 4 weeks during escalation): Liver function, kidney function, and pancreatic enzymes as a minimum.
At maintenance dose (every 8–12 weeks): Full panel to track ongoing metabolic improvements and screen for emerging concerns.
After reaching target dose (quarterly): Comprehensive blood test to monitor long-term changes in lipids, thyroid function, HbA1c, and nutritional status.
Track Your Health During Dose Escalation
Lola Health’s Core Health 45 blood test covers liver function, kidney function, thyroid hormones, HbA1c, full blood count, lipids, and key nutritional markers — all the biomarkers recommended for monitoring during weight management treatment.
View Core Health 45 Blood TestWeight Loss Results by Retatrutide Dosage
The relationship between retatrutide dosage and weight loss follows a clear dose-response curve, with higher doses producing greater results. However, the data also shows that even lower doses produce clinically meaningful weight loss.
| Dose | Weight Loss at 24 Weeks | Weight Loss at 48 Weeks | % Achieving ≥15% Loss (48 wks) |
|---|---|---|---|
| Placebo | −1.6% | −2.1% | 2% |
| 1 mg | −7.2% | −8.7% | — |
| 4 mg | −12.9% | −17.1% | 60% |
| 8 mg | −17.3% | −22.8% | 75% |
| 12 mg | −17.5% | −24.2% | 83% |
| 12 mg (Phase 3, 68 wks) | — | −28.7% | — |
Phase 2 data from Jastreboff et al., NEJM 2023 (338 participants, 48 weeks). Phase 3 data from TRIUMPH-4 trial (445 participants, 68 weeks). ≥15% loss column shows data from the Phase 2 trial only.
Three findings stand out. First, weight loss continues well beyond the 24-week primary endpoint — the 12 mg group lost −17.5% at 24 weeks but −24.2% at 48 weeks, meaning nearly 7 additional percentage points were lost in the second half of the study. Second, the 12 mg dose in Phase 3 produced even greater results (−28.7% at 68 weeks), suggesting that longer treatment duration yields additional benefit. Third, at the 12 mg dose, 100% of participants achieved at least 5% weight loss and 83% achieved at least 15% — a threshold associated with meaningful improvements in metabolic health markers.
Monitor Blood Markers at Each Dose Escalation Step
As retatrutide doses increase from 1mg to 12mg, liver enzymes, lipids, and blood sugar responses change. Blood testing at baseline and at key dose escalation points — especially when moving from 4mg to 8mg and beyond — helps your prescriber assess tolerability and decide when to hold or advance the dose.
All results reviewed by a doctor. Free delivery. Results in 2-3 working days.
Frequently Asked Questions About Retatrutide Dosage
What is the starting dose of retatrutide?
In clinical trials, the standard starting dose is 2 mg once weekly by subcutaneous injection. Phase 2 data showed that starting at 2 mg rather than 4 mg significantly reduced gastrointestinal side effects without compromising long-term weight loss outcomes. All Phase 3 TRIUMPH trial participants begin at 2 mg.
How long does it take to reach the maximum 12 mg dose?
The dose escalation to 12 mg takes approximately 16–20 weeks, with dose increases occurring every 4 weeks. The Phase 3 schedule follows the steps: 2 mg (weeks 1–4), 4 mg (weeks 5–8), 6 mg (weeks 9–12), 9 mg (weeks 13–16), and 12 mg (from week 17 onward). Some patients may require a longer escalation period if they experience significant side effects at a particular dose level.
Can you stay on a lower dose of retatrutide?
Yes. Not all patients need to reach 12 mg. Clinical trials tested maintenance doses of 4 mg, 8 mg (Phase 2), and 9 mg (Phase 3), all of which produced clinically significant weight loss. The 4 mg dose achieved −17.1% weight loss at 48 weeks, and the 9 mg dose achieved −26.4% at 68 weeks. The optimal dose depends on individual response and tolerability.
What happens if you skip the dose escalation and start at a high dose?
The Phase 2 trial provided direct evidence on this question. Participants in the 8 mg group who started at 4 mg (skipping the 2 mg step) experienced nausea rates of 60% compared to 17% in those who started at 2 mg. Skipping dose escalation dramatically increases gastrointestinal side effects without improving long-term weight loss. This is why gradual titration is considered essential.
What blood tests should I have before starting retatrutide?
A comprehensive baseline blood test should include liver function (ALT, AST, GGT), kidney function (creatinine, eGFR), pancreatic enzymes (amylase, lipase), thyroid hormones (TSH, free T4, free T3), HbA1c, fasting glucose, a full lipid panel, and a full blood count. These markers should be re-tested at each dose increase and regularly during maintenance. Lola Health’s Core Health 45 blood test covers these biomarkers.
When will retatrutide be available?
Retatrutide is currently in Phase 3 clinical trials (the TRIUMPH programme). Seven Phase 3 trials are expected to complete in 2026. If results are positive, Eli Lilly is expected to submit for regulatory approval, with potential FDA approval estimated in 2027 and MHRA approval for the UK following thereafter. As of early 2026, retatrutide is not available outside of clinical trials.
Get Your Baseline Blood Test
Whether you are considering weight management treatment or already on one, establishing baseline biomarker values is essential. Test 45 key health markers from home with results in 2 working days.
Shop Core Health 45 — £149References
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
- Eli Lilly and Company. Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial. Press release, December 11, 2025.
- Rosenstock J, Frias JP, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023;402(10401):529-544.
- Alshehri AA, et al. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 2024.
- Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30:2037-2048.
At-Home Blood Testing
Check your levels from home
Professional phlebotomist visit. Doctor-reviewed results in 2-5 days. Track your health with comprehensive blood panels.
→45-70 biomarkers tested · Venous blood draw · From £130